MA26673A1 - Composes pharmaceutiques - Google Patents

Composes pharmaceutiques

Info

Publication number
MA26673A1
MA26673A1 MA25728A MA25728A MA26673A1 MA 26673 A1 MA26673 A1 MA 26673A1 MA 25728 A MA25728 A MA 25728A MA 25728 A MA25728 A MA 25728A MA 26673 A1 MA26673 A1 MA 26673A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Application number
MA25728A
Other languages
English (en)
French (fr)
Inventor
Tolar Martin Michael
Holder Jurgensen Cynthia
Mary Daluge Susan
Howard Osterhout Martin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26673A1 publication Critical patent/MA26673A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA25728A 1998-08-13 1999-08-11 Composes pharmaceutiques MA26673A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9817623.3A GB9817623D0 (en) 1998-08-13 1998-08-13 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
MA26673A1 true MA26673A1 (fr) 2004-12-20

Family

ID=10837179

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25728A MA26673A1 (fr) 1998-08-13 1999-08-11 Composes pharmaceutiques

Country Status (36)

Country Link
US (3) US6608069B1 (enExample)
EP (1) EP1104422B1 (enExample)
JP (3) JP3631961B2 (enExample)
KR (1) KR20010085369A (enExample)
CN (2) CN1251676C (enExample)
AP (1) AP1408A (enExample)
AR (1) AR020154A1 (enExample)
AT (1) ATE259810T1 (enExample)
AU (1) AU775819B2 (enExample)
BR (1) BR9913020A (enExample)
CA (1) CA2340350A1 (enExample)
CO (1) CO5130007A1 (enExample)
DE (1) DE69914921T2 (enExample)
DK (1) DK1104422T3 (enExample)
EA (1) EA004139B1 (enExample)
EE (1) EE04721B1 (enExample)
ES (1) ES2215399T3 (enExample)
GB (1) GB9817623D0 (enExample)
HU (1) HUP0103637A3 (enExample)
ID (1) ID28723A (enExample)
IL (1) IL141318A0 (enExample)
IS (1) IS5843A (enExample)
MA (1) MA26673A1 (enExample)
MY (1) MY133393A (enExample)
NO (1) NO20010715L (enExample)
NZ (1) NZ509778A (enExample)
PE (1) PE20000952A1 (enExample)
PL (1) PL346055A1 (enExample)
PT (1) PT1104422E (enExample)
SI (1) SI1104422T1 (enExample)
SK (1) SK2222001A3 (enExample)
TR (1) TR200100448T2 (enExample)
TW (1) TWI224598B (enExample)
WO (1) WO2000009507A1 (enExample)
YU (1) YU11601A (enExample)
ZA (1) ZA200101186B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
EP1343502A2 (en) * 2000-11-17 2003-09-17 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
ES2262798T3 (es) * 2001-02-28 2006-12-01 Smithkline Beecham Corporation Derivados glicolicos de xantinas para tratar el sindrome del intestino irritable.
WO2003017964A1 (en) 2001-08-24 2003-03-06 Unilever N.V. Oral composition comprising an alkylhydroxybenzoate
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
KR100937620B1 (ko) 2001-11-09 2010-01-20 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ２ｂ 아데노신 수용체 길항제
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20040072848A1 (en) * 2002-02-26 2004-04-15 Huber Brian E Methods of treating irritable bowel syndrome and functional dyspepsia
JP4491344B2 (ja) 2002-06-17 2010-06-30 グラクソ グループ リミテッド 肝ｘ受容体アゴニストとしてのプリン誘導体
EP1658291B1 (en) * 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
GB0324086D0 (en) * 2003-10-14 2003-11-19 Glaxo Group Ltd Process for preparing a co-precipitate of a non-crystalline solid drug substance
WO2006004903A2 (en) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US7598379B2 (en) 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US20120108614A1 (en) * 2008-05-14 2012-05-03 Chong Jayhong A Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009140517A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2010039289A2 (en) 2008-05-14 2010-04-08 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
CN102105474B (zh) * 2008-05-30 2014-01-08 健泰科生物技术公司 嘌呤pi3k抑制剂化合物及使用方法
CN102260260B (zh) * 2010-05-24 2014-08-06 中国科学院上海药物研究所 8-苯基黄嘌呤类化合物、其制备方法、包含该化合物的药物组合物及其用途
CN102993203B (zh) * 2011-09-09 2015-11-25 温州医学院 8-苯基黄嘌呤类衍生物的制备及应用
US9502952B2 (en) 2012-10-12 2016-11-22 Persimmon Technologies, Corp. Hybrid motor
KR20160007598A (ko) * 2013-05-10 2016-01-20 님버스 아폴로, 인코포레이티드 Acc 억제제 및 이의 용도
US10208044B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
HK1221661A1 (zh) 2013-05-10 2017-06-09 Gilead Apollo, Llc Acc抑制剂和其用途
CN105358143B (zh) * 2013-05-10 2019-01-22 吉利德阿波罗公司 Acc抑制剂和其用途
EP4389749A1 (en) * 2022-12-20 2024-06-26 invIOs GmbH Substituted 3,7-dihydro-1h-purine-2,6-diones and use thereof
CN120435477A (zh) 2022-12-20 2025-08-05 英威欧斯有限公司 被取代的3,7-二氢-1h-嘌呤-2,6-二酮及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442125A (en) * 1978-06-26 1984-04-10 Oxford Hill, Ltd. Process for detaching or preventing attachment of microorganisms to a surface
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5015647A (en) 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
GB8826595D0 (en) 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
IL100088A (en) 1990-11-21 1995-07-31 Smithkline Beecham Corp FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
TW252044B (enExample) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
US5840302A (en) * 1993-11-10 1998-11-24 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
US5395831A (en) 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
GB9415529D0 (en) 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
WO1997034616A1 (en) 1996-03-18 1997-09-25 Medical Science Systems, Inc. A method for periodontal disease treatment
EP0812844B1 (de) 1996-06-07 2002-10-23 Hoechst Aktiengesellschaft Verwendung von Theophyllinderivaten zur Behandlung und Propylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
AU2640999A (en) 1998-02-26 1999-09-15 Zenyaku Kogyo Kabushiki Kaisha 1-azaindolizine derivatives
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
CA2393724A1 (en) 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US20020006915A1 (en) * 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
US6751206B1 (en) 2000-06-29 2004-06-15 Qualcomm Incorporated Method and apparatus for beam switching in a wireless communication system

Also Published As

Publication number Publication date
CN1149215C (zh) 2004-05-12
IS5843A (is) 2001-02-09
CO5130007A1 (es) 2002-02-27
NO20010715L (no) 2001-04-02
US6770267B2 (en) 2004-08-03
PT1104422E (pt) 2004-06-30
HUP0103637A2 (en) 2002-06-29
EE200100083A (et) 2002-06-17
JP2002522542A (ja) 2002-07-23
JP2004115534A (ja) 2004-04-15
CA2340350A1 (en) 2000-02-24
EE04721B1 (et) 2006-10-16
CN1251676C (zh) 2006-04-19
AR020154A1 (es) 2002-04-10
EP1104422A1 (en) 2001-06-06
AP2001002071A0 (en) 2001-03-31
MY133393A (en) 2007-11-30
HUP0103637A3 (en) 2002-10-28
WO2000009507A1 (en) 2000-02-24
SI1104422T1 (en) 2004-06-30
DK1104422T3 (da) 2004-06-14
PE20000952A1 (es) 2000-09-29
AU5732399A (en) 2000-03-06
EA200100127A1 (ru) 2001-10-22
JP2004137251A (ja) 2004-05-13
KR20010085369A (ko) 2001-09-07
BR9913020A (pt) 2001-05-08
NZ509778A (en) 2003-08-29
TWI224598B (en) 2004-12-01
ES2215399T3 (es) 2004-10-01
DE69914921D1 (en) 2004-03-25
ATE259810T1 (de) 2004-03-15
AU775819B2 (en) 2004-08-19
CN1323309A (zh) 2001-11-21
IL141318A0 (en) 2002-03-10
GB9817623D0 (en) 1998-10-07
ID28723A (id) 2001-06-28
JP3631961B2 (ja) 2005-03-23
DE69914921T2 (de) 2004-12-23
TR200100448T2 (tr) 2001-09-21
US20030032804A1 (en) 2003-02-13
YU11601A (sh) 2004-03-12
US20040034020A1 (en) 2004-02-19
ZA200101186B (en) 2002-02-12
AP1408A (en) 2005-05-06
HK1035195A1 (en) 2001-11-16
NO20010715D0 (no) 2001-02-12
PL346055A1 (en) 2002-01-14
EA004139B1 (ru) 2004-02-26
US6608069B1 (en) 2003-08-19
CN1515571A (zh) 2004-07-28
EP1104422B1 (en) 2004-02-18
SK2222001A3 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
MA26673A1 (fr) Composes pharmaceutiques
ID23299A (id) Formulasi-formulasi farmasi
DE69908021D1 (de) Ziprasidonhaltige Arzneimittel
ID27415A (id) Komposisi farmaseutik
NO20001776L (no) Medikamenter
NO20005913D0 (no) Legemiddelsammensetning
NO20005218D0 (no) Farmasøytisk aerosolpreparat
NO20010046D0 (no) Dolastatin-15-derivater
NO20005399D0 (no) Farmasøytisk preparat
NO996372L (no) Fast farmasøytisk preparat inneholdende benzofuanderivater
ID29089A (id) Sediaan farmasi moksifloksasin
DK1466615T3 (da) Farmaceutisk præparat
NO20015670L (no) Forbedrede farmasöytiske formuleringer
ID27201A (id) Komposisi farmasi
EP0850057A4 (en) Pharmaceutical compounds
NO20022606D0 (no) Farmasöytiske kombinasjoner
ID27150A (id) Sediaan levotiroksin bahan farmasi
ATE309838T1 (de) Pharmazeutisches implantat
EP1087957A4 (en) CONNECTIONS WITH SELF-INDUCTION
NO20014926D0 (no) Farmasöytiske forbindelser
FR2802423B1 (fr) Compositions pharmaceutiques
ID30032A (id) Formulasi farmasi
EP0923564A4 (en) Pharmaceutical compounds
IS6163A (is) Lyfjakomplex
EP1124557A4 (en) Pharmaceutical composition